Index to Volume 15

Author Index

- A -

ACCP 1995 Annual Meeting—Abstracts and Index of Authors, 361
ACCP 1995 Winter Practice and Research Forum—Abstracts and Index of Authors, 106
ACCP: Rewards and Advancements for Clinical Pharmacy Practitioners, 99
Ackerman BA: see Travaglini MT, et al, 260
Afshar M: see Larijani GE, et al, 36
Ahmed OI: see Wilt VM, et al, 732
Akers WS: see Johnson JA, et al, 150
Alsar MJ: see Soto J, et al, 781
Amory DW: see Wagner BKJ, et al, 42
Ando M: see Ando Y, et al, 345
Ando Y, Gotoh T, Kawaguchi Y, Tanaka Y, Sakashita N, Ando M: Intranasal L-threo-3,4,-dihydroxyphenylserine in Treating Diarrhea Associated With Familial Amyloidotic Polyneuropathy, 345
Applegate WB: see Johnson JA, et al, 150
Arndt GA, Reiss WG, Bathke KA, Springman SR, Kenny G: Computer-Assisted Continuous Infusion for the Delivery of Target-Controlled Infusions of Propofol During Outpatient Surgery, 512
Ashford JW: see Semla TP, et al, 495
Ausman RK: see Whipple JK, et al, 210
Ausman RK: see Whipple JK, et al, 592

- B -

Bailey TC: see Reichley RM, et al, 625
Bainbridge JL: see Fish DN, et al, 236
Balfour HH Jr: see Fletcher CV, et al, 701
Bander JJ: see Snider RD, et al, 747
Barbour MM, Hume AL, Lapane KL, Derby CA, Carleton RA: Predictors of Future Antihypertensive Use in Patients With Mildly Elevated Blood Pressure, 272
Barbour MM: see Hume AL, et al, 78
Basak J: see O'Connor TA, et al, 170
Bathke KA: see Arndt GA, et al, 512
Bauman JL: see Oberg KC, et al, 687
Beaty R: see Jick H, et al, 23
Bell L: Paul JE, et al, 49S
Bendayan R, Georgis W, Rafi-Tari S: Interaction of 3′-Azido-3′-Deoxythymidine With the Organic Base Transporter in a Cultured Renal Epithelium, 338
Benet LZ, Goyan JE: Bioequivalence and Narrow Therapeutic Index Drugs, 433
Berardi RR: see Welage LS, et al, 158
Berrettini W: Diagnostic and Genetic Issues of Depression and Bipolar Illness, 69S
Bertino JS Jr: see Holcombe BJ, et al, 806
Bhatt-Mehta V, Johnson CE, Donn SM, Spadoni V, Schork MA: Accuracy and Reliability of Dosing Equations to Individualize Theophylline Treatment of Apnea of Prematurity, 246
Billeter M: Rationale and Experience in Treating Suspected Hospital-Based Mixed Infections, 22S
Blackwell E, Loughlin K, Dumler F, Smythe M: Nabumetone-Associated Interstitial Nephritis, 669
Bleske BE, Warren EW, Rice TL, Gilligan LJ, Tait AR: Effect of High-Dose Sodium Bicarbonate on the Vasopressor Effects of Epinephrine During Cardiopulmonary Resuscitation, 660
Bleske BE, Welage LS, Warren EW, Brown MB, Shea MJ: Variations in Prothrombin Time and International Normalized Ratio over 24 Hours in Warfarin-Treated Patients, 709
Bleske BE: see Welage LS, et al, 158
Blissenbach HF: Use of Cost-Consequence Models in Managed Care, 59S
Bond CA, Raehl CL, Claesson C: International Pharmacy, 586
Bostom AG, Hume AL, Eaton CB, Laurino JP, Yanek LR, Regan M, McQuade WH, Craig WY, Perrone G, Jacques PF: The Effect of High-Dose Ascorbate Supplementation on Plasma Lipoprotein(a) Levels in Patients With Premature Coronary Heart Disease, 458
Bostrom BC: see Seay RE, et al, 52
Boucher BA: see Whipple JK, et al, 210
Breton AL: see Jick H, et al, 23
Briceland LL: see Preston SL, et al, 297
Briggs GC: see Teague AC, et al, 502
Brocks DR, Jamali F: Stereochemical Aspects of Pharmacotherapy, 551
Brooks MJ, Melnik J: The Refeeding Syndrome: An Approach to Understanding Its Complications and Preventing Its Occurrence, 713
Brophy MT: see Winward DB, et al, 765
Brown MB: see Bleske BE, et al, 709
Brunner LJ, DiPiro JT, Feldman S: High-Performance Capillary Electrophoresis in the Pharmaceutical Sciences, 1
Bryson SM: see Ho KK, et al, 754
Burgess E, Sargious P: Charcoal Hemoperfusion for Theophylline Overdose: Case Report and Proposal for Predicting Treatment Time, 621
Burke TG: see Geraets DR, et al, 441
Burm J-P: see Jhee SS, et al, 472
Burstein AH: Lamotrigine, 129
Butler IJ: see Mancias P, et al, 528

- C -

Caiola SM: see Holcombe BJ, et al, 806
Canada T: Octreotide- or Trimethoprim-Induced Hyperkalemia?, 814
Carleton RA: see Barbour MM, et al, 272
Carleton RA: see Hume AL, et al, 78
Carson SW: see Figg WD, et al, 693
Carter BL: see Porter JA, et al, 92
Claesson C: see Bond CA, et al, 586
Clifton GD: see Herrington AM, et al, 182
Coaker JS: see McKenney JM, et al, 565
Coburn JW: see Moore JG, et al, 742
Cohen D: see Semla TP, et al, 495
Cohen LJ: Introduction to Advances in the Diagnosis and Treatment of Depression, 67S
Como J: see Khoury Z, et al, 59
Conboy K, Welage LS, Walawander CA, Duffy LC, Welliver RC, Zielezny MA, DiPiro JT, Raebel MA, Grasela TH: Sepsis Syndrome and Associated Sequelae in Patients at High Risk for Gram-Negative Sepsis, 66
Cooney GF, Mochon M, Kaiser B, Dunn SP, Goldsmith B: Effects of Carbamazepine on Cyclosporine Metabolism in Pediatric Renal Transplant Recipients, 353
Cornish LA: see Odeh RM, et al, 648
Craig WY: see Bostom AG, et al, 458
Crawford SY: see Schumock GT, et al, 201

- D -

Daller JA: see Newsom L, et al, 789
Danziger LH: see Fish DN, et al, 279
Darnowski J: see Marchbanks K, et al, 451
Dean AD: see Jick H, et al, 176
Dechert RE: see Welage LS, et al, 158
Dehoorne-Smith ML: see Kale-Pradhan PB, et al, 673
Dempsey CL: Nursing Home-Acquired Pneumonia: Outcomes from a Clinical Process Improvement Program, 33S
Derby CA: see Barbour MM, et al, 272
Derby LE: see Jick H, et al, 428
DiFazio LT: see Wagner BKJ, et al, 42
DiPiro JT: Considerations for Therapy of Mixed Infections: Focus on Intraabdominal Infection, 15S
DiPiro JT: see Brunner LJ, et al, 1
DiPiro JT: see Conboy K, et al, 66
Dominguez RA, Goodnick PJ: Adverse Events After the Abrupt Discontinuation of Paroxetine, 778
Donn SM: see Bhatt-Mehta V, et al, 246
Dresler CM: see Schafers SJ, et al, 228
Ducharme MP, Munzenberger P: Severe Withdrawal Syndrome Possibly Associated With Cessation of a Midazolam and Fentanyl Infusion, 665
Dudley M: Bacterial Resistance Mechanisms to β-Lactam Antibiotics: Assessment of Management Strategies, 9S
Dudley MN: Management of Herpesvirus Infections in the Healthy Host, 43S
Dudley MN: see Marchbanks K, et al, 451
Duffy LC: see Conboy K, et al, 66
Dukes GE: see Figg WD, et al, 693
Dumler F: see Blackwell E, et al, 669
Dunn GH: see Snider RD, et al, 747
Dunn SP: see Cooney GF, et al, 353
Dunn-Kucharski VA: see Welage LS, et al, 158

- E -

Eaton CB: see Bostom AG, et al, 458
Einarson TR: see Ho KK, et al, 754
Eisdorfer C: see Semla TP, et al, 495
Elswick RK Jr: see McKenney JM, et al, 565
Erstad B: see Whipple JK, et al, 210
Erstad BL: see Newsom L, et al, 789
Esser MJ: see Whipple JK, et al, 210
Ewing JR: see Fagan SC, et al, 573

- F -

Fagan SC, Levine SR, Ewing JR, Ramadan NM, Welch KMA: Age and Carotid Artery Occlusive Disease Are Important Determinants of Cerebral Blood Flow Changes After Antihypertensive Therapy, 573
Feldman S: see Brunner LJ, et al, 1
Feresu SA: see Maponga CC, et al, 614
Figg WD, Dukes GE, Lesesne HR, Carson SW, Songer SS, Pritchard JF, Hermann DJ, Powell JR, Hak LJ: Comparison of Quantitative Methods to Assess Hepatic Function: Pugh's Classification, Indocyanine Green, Antipyrine, and Dextromethorphan, 693
Fish DN, Bainbridge JL, Peloquin CA: Variable Disposition of Ciprofloxacin in Critically Ill Patients Undergoing Continuous Arteriovenous Hemodiafiltration, 236
Fish DN, Piscitelli SC, Danziger LH: Development of Resistance During Antimicrobial Therapy: A Review of Antibiotic Classes and Patient Characteristics in 173 Studies, 279
Fish JT, Guay DRP, Straka RJ: Antihypertensive Drug Use in the Long-Term Care Facility: A Pilot Study and Review of the Literature, 785
Fisher DM: see Larijani GE, et al, 36
Flanigan MJ: see Min DI, et al, 164
Fletcher CV, Henry WK, Noormohamed SE, Rhame FS, Balfour HH Jr: The Effect of Cimetidine and Ranitidine Administration With Zidovudine, 701
Freels S: see Semla TP, et al, 495
Freeman CD: see Lipsy RJ, et al, 48

- G -

Gardner SF, Skelton DR, Rollins SD, Hastings JK: Community Pharmacy Data Bases to Identify Patients at High Risk for Hypercholesterolemia, 292
Garnett WR: see Teague AC, et al, 502
Georgis W: see Bendayan R, et al, 338
Geraets DR, Hoehns JD, Burke TG, Grover-McKay M: Thrombolytic-Associated Cholesterol Emboli Syndrome: Case Report and Literature Review, 441
Gibaldi M: Vertical Integration: The Drug Industry

and Prescription Benefits Managers, 265
Gill MA: see Jhee SS, et al, 472
Gilligan LJ: see Bleske BE, et al, 660
Gillum JG, Johnson M, Lavoie S, Venitz J: Flucytosine Dosing in an Obese Patient With Extrameningeal Cryptococcal Infection, 251
Goldsmith B: see Cooney GF, et al, 353
Goodnick PJ: see Dominguez RA, et al, 778
Gora-Harper ML, Sunahara JF, Gray MS: Intranasal Butorphanol-Induced Apraxia Reversed by Naloxone, 798
Gorelick P: see Semla TP, et al, 495
Gotoh T: see Ando Y, et al, 345
Gottlieb MS: see Whipple JK, et al, 210
Gottlieb MS: see Whipple JK, et al, 592
Goyan JE: see Benet LZ, et al, 433
Graf M: see Whipple JK, et al, 592
Grasela TH: see Conboy K, et al, 66
Gratz I: see Larijani GE, et al, 36
Gray MS: see Gora-Harper ML, et al, 798
Greenberg ML: see Ho KK, et al, 754
Greenway FL: see Greenway SE, et al, 357
Greenway SE, Pack AT, Greenway FL: Treatment of Depression With Cyproheptadine, 357
Grover-McKay M: see Geraets DR, et al, 441
Guay DRP: see Fish JT, et al, 785
Guay DRP: The Emerging Role of Valproate in Bipolar Disorder and Other Psychiatric Disorders, 631
Gums JG: see Wilt VM, et al, 732

- H -

Haith LR: see Travaglini MT, et al, 260
Hak LJ: see Figg WD, et al, 693
Hare BL: see Kale-Pradhan PB, et al, 673
Harman E: see Jick H, et al, 23
Hartnett KR: see Whipple JK, et al, 592
Hastings JK: see Gardner SF, et al, 292
Havlichek DH: see Stein GE, 727
Hendeles L, Breton AL, Beaty R, Harman E: Therapeutic Equivalence of a Generic Slow-Release Theophylline Tablet, 26
Hendeles L, Jenkins J, Temple R: Revised FDA Labeling Guideline for Theophylline Oral Dosage Forms, 409
Henry WK: see Fletcher CV, et al, 701
Hermann DJ: see Figg WD, et al, 693
Herrington AM, Clifton GD: Toxicology and Management of Acute Drug Ingestions in Adults, 182
Hess M: see Whipple JK, et al, 210
Higgins MJ: see Kale-Pradhan PB, et al, 673
Ho KK, Bryson SM, Thiessen JJ, Greenberg ML, Einarson TR, Leson CL: The Effects of Age And Chemotherapy on Gentamicin Pharmacokinetics and Dosing in Pediatric Oncology Patients, 754
Hoehns JD: see Geraets DR, et al, 441
Hoey LL, Joslin SM, Nahum A, Vance-Bryan K: Prolonged Neuromuscular Blockade in Two Critically Ill Patients Treated With Atracurium, 254
Hoey LL: see Johanning RJ, et al, 773
Hoey LL: see Johnson SV, et al, 579
Hoey LL: see Tschida SJ, et al, 533
Hoey LL: see Tschida SJ, et al, 540
Hoey LL: see Tschida SJ, et al, 546
Holcombe BJ, Thorn DB, Strausburg KM, Ponto JA, Caiola SM, Powers T, Bertino JS Jr, Leitinger EA, Robinson LA: Analysis of the Practice of Nutrition Support Pharmacy Specialists, 806
Hume AL, Barbour MM, Lapane KL, Carleton RA: Is Antidepressant Use Changing? Prevalence and Clinical Correlates in Two New England Communities, 78
Hume AL: see Barbour MM, et al, 272
Hume AL: see Bostom AG, et al, 458

- J -

Jacques PF: see Bostom AG, et al, 458
Jamali F: see Brocks DR, et al, 551
Jancik JT: see Whipple JK, et al, 210
Jaworski DA: see Kale-Pradhan PB, et al, 673
Jenkins J: see Hendeles L, et al, 409
Jewell MA: Quantitative Methods For Quality Improvement, 27S
Jhee SS, Kern JW, Burm J-P, Yellin AE, Gill MA: Piperacillin-Tazobactam Pharmacokinetics in Patients With Intraabdominal Infections, 472
Jick H, Derby LE: A Large Population-Based Follow-Up Study of Trimethoprim-Sulfamethoxazole, Trimethoprim, and Cephalexin for Uncommon Serious Drug Toxicity, 428
Jick H, Myers MW, Dean AD: The Risk of Sulfasalazine- and Mesalazine-Associated Blood Disorders, 176
Jick H: Drug-Associated Asymptomatic Elevations of Transaminase in Drug Safety Assessments, 23
Jick SS, Myers MW: A Study of Danazol's Safety, 740
Johanning RJ, Zaske DE, Tschida SJ, Johnson SV, Hoey LL, Vance-Bryan K: A Retrospective Study of Sodium Nitroprusside Use and Assessment of the Potential Risk of Cyanide Poisoning, 773
Johnson CE: see Bhatt-Mehta V, et al, 246
Johnson JA, Akers WS, Miller ST, Applegate WB: Lymphocyte β_2-Receptor Activity, Metoprolol Kinetics, and Response to Metoprolol in Hypertensive Black Men, 150
Johnson M: see Gillum JG, et al, 251
Johnson SV, Hoey LL, Vance-Bryan K: Inappro-priate Vancomycin Prescribing Based on Criteria from the Centers for Disease Control and Prevention, 579
Johnson SV: see Johanning RJ, et al, 773
Johnston TP: see Porter JA, et al, 92
Joslin SM: see Hoey LL, et al, 254
Jusko WJ: see Ko HC, et al, 509

- K -

Kaiser B: see Cooney GF, et al, 353
Kale-Pradhan PB, Dehoorne-Smith ML, Jaworski DA,

Hare BL, Provenzano R, Higgins MJ: Evaluation of Plasmapheresis on the Removal of Tobramycin, 673
Karschner JK: see Khoury Z, et al, 59
Katona BG: see Zimmermann AE, et al, 85
Kawaguchi Y: see Ando Y, et al, 345
Kenny G: see Arndt GA, et al, 512
Kern JW: see Jhee SS, et al, 472
Khoury Z, Schlicht JR, Como J, Karschner JK, Shapiro AP, Mook WJ, Weber RJ: The Effect of Prophylactic Nifedipine on Renal Function in Patients Administered Contrast Media, 59
Kino KJ, Wittkowsky AK: Influence of Bile Acid Replacement on Cyclosporine Absorption in a Patient With Jejunoileal Bypass, 350
Kino KJ: see Wittkowsky AK, et al, 517
Ko HC, Jusko WJ: Pharmacodynamic Modeling of Finasteride, a 5α-Reductase Inhibitor, 509
Kolinski RJ: see McKenney JM, et al, 565
Kradjan WA, Takeuchi KY, Opheim KE, Wood FC Jr: Pharmacokinetics and Pharmacodynamics of Glipizide After Once-Daily and Divided Doses, 465
Kramer L: see Mancias P, et al, 528
Kruse JA: see Snider RD, et al, 747

- L -

Lampasona V: Introduction to Bacterial Resistance and Assessing Outcomes, 1S
Lapane KL: see Barbour MM, et al, 272
Lapane KL: see Hume AL, et al, 78
Larijani GE, Gratz I, Afshar M, McDonald PA, Fisher DM: The Effect of Isoflurane versus Balanced Anesthesia on Rocuronium's Pharmacokinetics and Infusion Requirement, 36
Larson TA: see Seay RE, et al, 52
Laufman LR: see Sullivan BA, et al, 600
Laurino JP: see Bostom AG, et al, 458
Lavoie S: see Gillum JG, et al, 251
Lee DK: see Matsuyama JR, et al, 608
Leitinger EA: see Holcombe BJ, et al, 806
Lesesne HR: see Figg WD, et al, 693
Leson CL: see Ho KK, et al, 754
Levine SR: see Fagan SC, et al, 573
Lewis KS: see Whipple JK, et al, 210
Lewis KS: see Whipple JK, et al, 592
Lipsy RJ, Freeman CD: Hemodynamic Effects of Intravenous Famotidine in Critically Ill Patients, 48
Loughlin K: see Blackwell E, et al, 669
Luchins D: see Semla TP, et al, 495

- M -

Mancias P, Kramer L, Butler IJ: Amoxapine Overdose in a Young Man: A Transient Mitochondrial Abnormality?, 528
Maponga CC, Feresu SA: A Community-Based Clinical Pharmacy Teaching, Research, and Service Program in Zimbabwe, 614
Marchbanks K, Dudley MN, Posner MR, Darnowski J: Pharmacokinetics and Pharmacodynamics of High-Dose Zidovudine Administered as a Continuous Infusion in Patients With Cancer, 451
Mather D: see Tschida SJ, et al, 546
Matsuyama JR, Lee DK: The Development of Clinical Practice Guidelines for Treatment of Peptic Acid Diseases in a VA Ambulatory Care Clinic, 608
Mauskopf JA: Paul JE, et al, 49S
McCall CY: see Wade WE, et al, 216
McDonald PA: see Larijani GE, et al, 36
McKenney JM, Proctor JD, Wright JT Jr, Kolinski RJ, Elswick RK Jr, Coaker JS: The Effect of Supplemental Dietary Fat on Plasma Cholesterol Levels in Lovastatin-Treated Hypercholesterolemic Patients, 565
McKindley DS: see Whipple JK, et al, 210
McKinnis R: see Sullivan BA, et al, 600
McQuade WH: see Bostom AG, et al, 458
McSorley DJ: see Moore JG, et al, 742
Medicus-Bringa M: see Whipple JK, et al, 592
Meese MG: see Schwenk MH, et al, 522
Melnik J: see Brooks MJ, et al, 713
Mihm LB, Rathbun RC, Resman-Targoff BH: Hyperkalemia Associated With High-Dose Trimethoprim-Sulfamethoxazole in a Patient With the Acquired Immunodeficiency Syndrome, 793
Miller ST: see Johnson JA, et al, 150
Min DI, Noormohamed SE, Flanigan MJ: Effect of Erythromycin on Ethanol's Pharmacokinetics and Perception of Intoxication, 164
Mochon M: see Cooney GF, et al, 353
Mook WJ: see Khoury Z, et al, 59
Moore JG, Coburn JW, Sanders MC, McSorley DJ, Sirgo MA: Effects of Sucralfate and Ranitidine on Aluminum Concentrations in Elderly Volunteers, 742
Moore LM: see Wilt VM, et al, 732
Morrison RC: see Travaglini MT, et al, 260
Mummaw NL: see Stein GE, 727
Munzenberger P: see Ducharme MP, et al, 665
Murry DJ, Synold TW, Pui C-H, Rodman JH: Renal Function and Methotrexate Clearance in Children With Newly Diagnosed Leukemia, 144
Myers MW: see Jick H, et al, 176
Myers MW: see Jick SS, et al, 740

- N -

Naderer OJ: see Schumock GT, et al, 201
Nahum A: see Hoey LL, et al, 254
Nahum A: see Tschida SJ, et al, 533
Nakazato PZ: see Newsom L, et al, 789
Newsom L, Erstad BL, Nakazato PZ, Daller JA: Falsely Decreased Total Serum Calcium Concentration Associated With Iron Dextran Injection, 789
Nightingale CH: Cost Comparison of β_2-Agonist Bronchodilators Used in the Treatment of Asthma, 677
Nightingale CH: see Sullivan MC, et al, 479
Noormohamed SE: see Fletcher CV, et al, 701

Noormohamed SE: see Min DI, et al, 164

- O -

O'Connor TA, Basak J, Parker S: The Effect of Three Different Ranitidine Dosage Regimens on Reducing Gastric Acidity and Volume in Ambulatory Surgical Patients, 170
O'Leary MC: see Seay RE, et al, 52
Oberg KC, Bauman JL: QT Interval Prolongation and Torsades de Pointes Due to Erythromycin Lactobionate, 687
Odeh RM, Cornish LA: Natural Antioxidants for the Prevention of Atherosclerosis, 648
Oki JC: Dyslipidemias in Patients With Diabetes Mellitus: Classification and Risks and Benefits of Therapy, 317
Opheim KE: see Kradjan WA, et al, 465

- P -

Pack AT: see Greenway SE, et al, 357
Palmer WK: see Porter JA, et al, 92
Parker S: see O'Connor TA, et al, 170
Patton ML: see Travaglini MT, et al, 260
Paul JE, Mauskopf JA, Bell L: Cost-Consequence Models for Varicella-Zoster Virus Infections, 49S
Paveza GJ: see Semla TP, et al, 495
Peloquin CA: see Fish DN, et al, 236
Perrone G: see Bostom AG, et al, 458
Piscitelli SC: see Fish DN, et al, 279
Plaisance KI: see Zimmermann AE, et al, 85
Polk R: Vancomycin Prescribing in the Era of Vancomycin-Resistant Enterococci, 682
Ponto JA: see Holcombe BJ, et al, 806
Porter JA, Carter BL, Johnston TP, Palmer WK: Effects of Pravastatin on Plasma Lipid Concentrations in Poloxamer 407-Induced Hyperlipidemic Rats, 92
Posner MR: see Marchbanks K, et al, 451
Powell JR: see Figg WD, et al, 693
Powers T: see Holcombe BJ, et al, 806
Preston SL, Briceland LL: Single Daily Dosing of Aminoglycosides, 297
Pritchard JF: see Figg WD, et al, 693
Proctor JD: see McKenney JM, et al, 565
Provenzano R: see Kale-Pradhan PB, et al, 673
Pui C-H: see Murry DJ, et al, 144

- Q -

Quebbeman EJ: see Whipple JK, et al, 210
Quebbeman EJ: see Whipple JK, et al, 592
Quintiliani R: see Sullivan MC, et al, 479

- R -

Raber SR: see Schumock GT, et al, 201
Raebel MA: see Conboy K, et al, 66
Raehl CL: see Bond CA, et al, 586
Rafi-Tari S: see Bendayan R, et al, 338
Ramadan NM: see Fagan SC, et al, 573
Rathbun RC: see Mihm LB, et al, 793
Ray TR: see Rodman DP, et al, 801
Regan M: see Bostom AG, et al, 458
Reichley RM, Ritchie DJ, Bailey TC: Analysis of Various Creatinine Clearance Formulas in Predicting Gentamicin Elimination in Patients With Low Serum Creatinine, 625
Reiss WG: see Arndt GA, et al, 512
Resman-Targoff BH: see Mihm LB, et al, 793
Rhame FS: see Fletcher CV, et al, 701
Rice TL: see Bleske BE, et al, 660
Riesenman C: Antidepressant Drug Interactions and the Cytochrome P450 System: A Critical Appraisal, 84S
Ritchie DJ: see Reichley RM, et al, 625
Robinson LA: see Holcombe BJ, et al, 806
Rodman DP, Stevenson TL, Ray TR: Phenytoin Malabsorption After Jejunostomy Tube Delivery, 801
Rodman JH: see Murry DJ, et al, 144
Rodvold KA: see Schumock GT, et al, 201
Rollins SD: see Gardner SF, et al, 292
Rybak MJ, Palmer SM: Vancomycin-Resistant Enterococci, 684

- S -

Sacristan JA: see Soto J, et al, 781
Sakashita N: see Ando Y, et al, 345
Saklad SR: Pharmacoeconomic Issues in the Treatment of Depression, 76S
Sanders MC: see Moore JG, et al, 742
Sargious P: see Burgess E, et al, 621
Schafers SJ, Dresler CM: Update on Talc, Bleomycin, and the Tetracyclines in the Treatment of Malignant Pleural Effusions, 228
Schlicht JR: see Khoury Z, et al, 59
Schork MA: see Bhatt-Mehta V, et al, 246
Schumock GT, Raber SR, Crawford SY, Naderer OJ, Rodvold KA: National Survey of Once-Daily Dosing of Aminoglycoside Antibiotics, 201
Schwenk MH, St. Peter WL, Meese MG, Singhal PC: Acetazolamide Toxicity and Pharmacokinetics in Patients Receiving Hemodialysis, 522
Scott GE: see Wagner BKJ, et al, 42
Seay RE, Larson TA, Toscano JP, Bostrom BC, O'Leary MC, Uden DL: Pharmacokinetics of Fluconazole in Immune-Compromised Children With Leukemia or Other Hematologic Disease, 52
Segars LW: see Thompson DF, et al, 487
Semla TP, Cohen D, Freels S, Paveza GJ, Ashford JW, Gorelick P, Luchins D, Eisdorfer C: Psychotropic Drug Use in Relation to Psychiatric Symptoms in Community-Living Persons With Alzheimer's Disease, 495
Shapiro AP: see Khoury Z, et al, 59
Shea MJ: see Bleske BE, et al, 709
Shea MJ: see Welage LS, et al, 158
Singhal PC: see Schwenk MH, et al, 522

Sirgo MA: see Moore JG, et al, 742
Skelton DR: see Gardner SF, et al, 292
Smolarek RT: see Zimmerman CR, et al, 220
Smythe M: see Blackwell E, et al, 669
Snider RD, Kruse JA, Bander JJ, Dunn GH: Accuracy of Estimated Creatinine Clearance in Obese Patients With Stable Renal Function in the Intensive Care Unit, 747
Songer SS: see Figg WD, et al, 693
Soto J, Alsar MJ, Sacristan JA: Assessment of the Time Course of Drugs With Inhibitory Effects on Hepatic Metabolic Activity Using Successive Salivary Caffeine Tests, 781
Spadoni V: see Bhatt-Mehta V, et al, 246
Spotnitz AJ: see Wagner BKJ, et al, 42
Springman SR: see Arndt GA, et al, 512
St. Peter WL: see Schwenk MH, et al, 522
Stanley HR: see Teague AC, et al, 502
Stein GE, Mummaw NL, Havlichek DH: A Preliminary Study of Clarithromycin versus Doxycycline in the Treatment of Nongonococcal Urethritis and Mucopurulent Cervicitis, 727
Stergachis A: Introduction to Treatment of Herpesvirus Infections Supplement, 39S
Stergachis A: Overview of Cost-Consequence Modeling in Outcomes Research, 40S
Stevenson JG: see Zimmerman CR, et al, 220
Stevenson TL: see Rodman DP, et al, 801
Stimmel GL: How To Counsel Patients About Depression and Its Treatment, 100S
Straka RJ: see Fish JT, et al, 785
Strausburg KM: see Holcombe BJ, et al, 806
Sullivan BA, McKinnis R, Laufman LR: Quality of Life in Patients With Metastatic Colorectal Cancer Receiving Chemotherapy: A Randomized, Double-Blind Trial Comparing 5-FU versus 5-FU With Leucovorin, 600
Sullivan MC, Nightingale CH, Quintiliani R, Sweeney KR: Comparison of the Pharmacodynamic Activity of Cefotaxime plus Metronidazole With Cefoxitin and Ampicillin plus Sulbactam, 479
Sunahara JF: see Gora-Harper ML, et al, 798
Sweeney KR: see Sullivan MC, et al, 479
Synold TW: see Murry DJ, et al, 144

- T -

Tait AR: see Bleske BE, et al, 660
Takeuchi KY: see Kradjan WA, et al, 465
Tanaka Y: see Ando Y, et al, 345
Teague AC, Garnett WR, Briggs GC, Stanley HR: The Effect of Age and Everyday Exercise on Steady-State Plasma Digoxin Concentrations, 502
Temple R: see Hendeles L, et al, 409
Thiessen JJ: see Ho KK, et al, 754
Thompson DF, Segars LW: Publication Rates in U.S. Schools and Colleges of Pharmacy, 1976–1992, 487
Thorn DB: see Holcombe BJ, et al, 806
Thornsberry C: Trends in Antimicrobial Resistance Among Today's Bacterial Pathogens, 3S
Toscano JP: see Seay RE, et al, 52
Travaglini MT, Morrison RC, Ackerman BA, Haith LR, Patton ML: Toxic Epidermal Necrolysis After Initiation of Felbamate Therapy, 260
Tschida SJ, Hoey LL, Mather D, Vance-Bryan K: Train-of-Four: To Use or Not to Use, 546
Tschida SJ, Hoey LL, Nahum A, Vance-Bryan K: Atracurium Resistance in a Critically Ill Patient, 533
Tschida SJ, Hoey LL, Vance-Bryan K: Inconsistency With Train-of-Four Monitoring in a Critically Ill Paralyzed Patient, 540
Tschida SJ: see Johanning RJ, et al, 773

- U, V -

Uden DL: see Seay RE, et al, 52
Vance-Bryan K: see Hoey LL, et al, 254
Vance-Bryan K: see Johanning RJ, et al, 773
Vance-Bryan K: see Johnson SV, et al, 579
Vance-Bryan K: see Tschida SJ, et al, 533
Vance-Bryan K: see Tschida SJ, et al, 540
Vance-Bryan K: see Tschida SJ, et al, 546
Venitz J: see Gillum JG, et al, 251

- W -

Wade WE, McCall CY: Pharmacist-Managed Aminoglycoside Therapy in Combination With a β-Lactam Agent in the Treatment of Nosocomial Pneumonia in Critically Ill Patients, 216
Wagner BKJ, DiFazio LT, Amory DW, Scott GE, Spotnitz AJ: Hemodynamic Effects of Intravenous Famotidine in Patients Undergoing Cardiac Surgery, 42
Walawander CA: see Conboy K, et al, 66
Warren EW: see Bleske BE, et al, 660
Warren EW: see Bleske BE, et al, 709
Weber RJ: see Khoury Z, et al, 59
Welage LS, Dunn-Kucharski VA, Berardi RR, Shea MJ, Dechert RE, Bleske BE: Comparative Evaluation of the Hemodynamic Effects of Oral Cimetidine, Ranitidine, and Famotidine as Determined by Echocardiography, 158
Welage LS: see Bleske BE, et al, 709
Welage LS: see Conboy K, et al, 66
Welch KMA: see Fagan SC, et al, 573
Welliver RC: see Conboy K, et al, 66
Wesley LC: see Whipple JK, et al, 210
Whipple JK, Lewis KS, Quebbeman EJ, Esser MJ, Gottlieb MS, McKindley DS, Hess M, Boucher BA, Jancik JT, Wesley LC, Erstad B, Ausman RK: Current Patterns of Prescribing and Administering Morphine in Trauma Patients, 210
Whipple JK, Lewis KS, Quebbeman EJ, Wolff M, Gottlieb MS, Medicus-Bringa M, Hartnett KR, Graf M, Ausman RK: Analysis of Pain Management in Critically Ill Patients, 592
Wilt VM, Gums JG, Ahmed OI, Moore LM: Outcome Analysis of a Pharmacist-Managed Anticoagulation

Service, 732
Winward DB, Brophy MT: Acute Renal Failure After Administration of Intravenous Immunoglobulin: Review of the Literature and Case Report, 765
Wittkowsky AK, Kino KJ: Heparin Monitoring in Acute Thrombosis Associated With Antiphospholipid Antibody Syndrome, 517
Wittkowsky AK: see Kino KJ, et al, 350
Wolff M: see Whipple JK, et al, 592
Wood FC Jr: see Kradjan WA, et al, 465
Wright JT Jr: see McKenney JM, et al, 565

- Y, Z -

Yanek LR: see Bostom AG, et al, 458
Yellin AE: see Jhee SS, et al, 472
Zaske DE: see Johanning RJ, et al, 773
Zielezny MA: see Conboy K, et al, 66
Zimmerman CR, Smolarek RT, Stevenson JG: A Computerized System to Improve Documentation and Reporting of Pharmacists' Clinical Interventions, Cost Savings, and Workload Activities, 220
Zimmermann AE, Katona BG, Plaisance KI: Association of Vancomycin Serum Concentrations With Outcomes in Patients With Gram-Positive Bacteremia, 85

- A -

ACCP 1995 Annual Meeting, abstracts and index of authors, 361
Acetazolamide toxicity and pharmacokinetics in patients receiving hemodialysis, 522
Acknowledgment of academic reviewers for 1995, 816
Aluminum concentrations in elderly volunteers, effects of sucralfate and ranitidine on, 742
Alzheimer's disease, psychotropic drug use in relation to psychiatric symptoms in community-living persons with, 495
Aminoglycoside antibiotics, national survey of once-daily dosing of, 201
Aminoglycoside therapy in combination with a beta-lactam agent for nosocomial pneumonia in critically ill patients, pharmacist-managed, 216
Aminoglycosides, single daily dosing of, 297
Amoxapine overdose in a young man: a transient mitochondrial abnormality?, 528
Ampicillin plus sulbactam and cefoxitin vs cefotaxime plus metronidazole, comparison of the pharmacodynamic activity of, 479
Anticoagulation service, outcome analysis of a pharmacist-managed, 732
Antidepressant drug interactions and the cytochrome p450 system: a critical appraisal, 84S
Antidepressant use, is it changing? prevalence and clinical correlates in two New England communities, 78
Antihypertensive drug use in the long-term care facility: a pilot study and review of the literature, 785
Antihypertensive therapy, age and carotid artery occlusive disease are important determinants of cerebral blood flow changes after, 573
Antihypertensive use in patients with mildly elevated blood pressure, predictors of future use, 272
Antimicrobial reistance, development of during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies, 279
Antimicrobial resistance, trends in among today's bacterial pathogens, 3S
Antioxidants, natural, for the prevention of atherosclerosis, 648
Antiphospholipid antibody syndrome, heparin monitoring in acute thrombosis associated with, 517
Antipyrine, comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, and dextromethorphan, 693
Apnea of prematurity, accuracy and reliability of dosing equations to individualize theophylline treatment of, 246
Apraxia induce by intranasal butorphanol and reversed by naloxone, 798
Ascorbate supplementation, the effect of high-dose on plasma lipoprotein(a) levels in patients with premature coronary heart disease, 458
Asthma, cost comparison of β_2-agonist bronchodilators used in the treatment of, 677
Atherosclerosis, natural antioxidants for the prevention of, 648
Atracurium resistance in a critically ill patient, 533
Atracurium, prolonged neuromuscular blockade in two critically ill patients treated with, 254

- B -

Bacterial resistance mechanisms to β-lactam antibiotics: assessment of management strategies, 9S
Beta-2-agonist bronchodilators used in the treatment of asthma, cost comparison of, 677
Beta-lactam agent in combination with an aminoglycoside for nosocomial pneumonia in critically ill patients, pharmacist-managed, 216
Beta-lactam antibiotics, bacterial resistance mechanisms to, assessment of management strategies, 9S
Beta-2-receptor activity (lymphocyte), metoprolol kinetics, and response to metoprolol in hypertensive black men, 150
Bile acid replacement, influence on cyclosporine absorption in a patient with jejunoileal bypass, 350
Bioequivalence and narrow therapeutic index drugs, 433
Bipolar illness and depression, diagnostic and genetic issues of, 69S
Bleomycin, talc, and the tetracyclines in the treatment of malignant pleural effusions, update on, 228
Blood disorders, the risk of sulfasalazine- and mesalazine-associated, 176
Butorphanol (intranasal)-induced apraxia reversed by naloxone, 798

- C -

Cancer, metastatic colorectal, quality of life in patients with receiving chemotherapy: 5-FU versus 5-FU with leucovorin, 600
Carbamazepine, effects of on cyclosporine metabolism in pediatric renal transplant recipients, 353
Cefotaxime plus metronidazole vs cefoxitin and ampicillin plus sulbactam, comparison of the pharmacodynamic activity of, 479
Cefoxitin and ampicillin plus sulbactam vs cefotaxime plus metronidazole, comparison of the pharmacodynamic activity of, 479
Cephalexin, trimethoprim-sulfamethoxazole, and

trimethoprim, uncommon serious drug toxicity, a large population-based follow-up study of, 428
Cerebral blood flow changes after antihypertensive therapy, age and carotid artery occlusive disease are important determinants of, 573
Charcoal hemoperfusion for theophylline overdose, a case report and proposal for predicting treatment time, 621
Cholesterol emboli syndrome, thrombolytic-associated: case report and literature review, 441
Cimetidine and ranitidine administration, the effect of, with zidovudine, 701
Cimetidine, ranitidine, and famotidine, comparative evaluation of the hemodynamic effects of oral, as determined by echocardiography, 158
Ciprofloxacin, variable disposition of in critically ill patients undergoing continuous arteriovenous hemodiafiltration, 236
Clarithromycin versus doxycycline in the treatment of nongonococcal urethritis and mucopurulent cervicitis, a preliminary study of, 727
Clinical pharmacy practitioners, rewards and advancements for, 99
Community pharmacy data bases to identify patients at high risk for hypercholesterolemia, 292
Computer-assisted continuous infusion for the delivery of target-controlled infusions of propofol during outpatient surgery, 512
Computerized system to improve documentation and reporting of pharmacists' clinical interventions, cost savings, and workload activities, 220
Contrast media, the effect of prophylactic nifedipine on renal function in patients administered, 59
Cost-consequence modeling in outcomes research, 40S
Creatinine clearance formulas in predicting gentamicin elimination in patients with low serum creatinine, analysis of various, 625
Creatinine clearance, accuracy of estimated in obese patients with stable renal function in the intensive care unit, 747
Cryptococcal infection, flucytosine dosing in an obese patient with extrameningeal, 251
Cyanide poisoning, the potential risk of with nitroprusside use, 773
Cyclosporine absorption in a patient with jejunoileal bypass, influence of bile acid replacement on, 350
Cyclosporine metabolism in pediatric renal transplant recipients, effects of carbamazepine on, 353
Cyproheptadine, treatment of depression with, 357
Cytochrome p450 system and antidepressant drug interactions, 84S

- D -

Danazol's safety, a study of, 740
Data bases, community pharmacy, to identify patients at high risk for hypercholesterolemia, 292
Depression and bipolar illness, diagnostic and genetic issues of, 69S
Depression and its treatment, how to counsel patients about, 100S
Depression, pharmacoeconomic issues in the treatment of, 76S
Depression, treatment of with cyproheptadine, 357
Dextromethorphan, comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, and antipyrine, 693
Diabetes mellitus, classification and risks and benefits of therapy in patients with dyslipidemias and, 317
Digoxin, steady-state plasma concentrations, the effect of exercise and age on, 502
Dihydroxyphenylserine, intranasal L-threo, in treating diarrhea associated with familial amyloidotic polyneuropathy, 345
Doxycycline versus clarithromycin in the treatment of nongonococcal urethritis and mucopurulent cervicitis, a preliminary study of, 727
Drug ingestions, acute, toxicology and management of in adults, 182
Drug-associated asymptomatic elevations of transaminase in drug safety assessments, 23
Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy, 317

- E -

Electrophoresis, high-performance capillary, use in the pharmaceutical sciences, 1
Epinephrine, effect of high-dose sodium bicarbonate on the vasopressor effects of, during cardiopulmonary resuscitation, 660
Erythromycin lactobionate, QT nterval prolongation and torsades de pointes due to, 687
Erythromycin, effect of on ethanol's pharmacokinetics and perception of intoxication, 164
Ethanol's pharmacokinetics and perception of intoxication, effect of erythromycin, 164
Exercise, the effect of, and age on steady-state plasma digoxin concentrations, 502

- F -

Famotidine in critically ill patients, hemodynamic effects of intravenous, 48
Famotidine, cimetidine, and ranitidine, compara-tive evaluation of the hemodynamic effects of oral, as determined by echocardiography, 158
Famotidine, in patients undergoing cardiac surgery, hemodynamic effects of intravenous, 42
Fat, the effect of supplemental, on plasma cholesterol levels in lovastatin-treated hypercholesterolemic patients, 565
Felbamate, toxic epidermal necrolysis after initiation of therapy with, 260
Fentanyl and midazolam infusion, severe withdrawal syndrome possibly associated with cessation of, 665
Finasteride, a 5α-reductase inhibitor, pharmaco-

dynamic modeling of, 509
Fluconazole, pharmacokinetics of in immune-compromised children with leukemia or other hematologic disease, 52
Flucytosine dosing in an obese patient with extrameningeal cryptococcal infection, 251

- G -

Gastric acidity and volume in ambulatory surgica patients, the effect of three different dosage regimens of ranitidine on, 170
Gentamicin elimination in patients with low serum creatinine, analysis of various creatinine clearance formulas in predicting, 625
Gentamicin pharmacokinetics and dosing in pediatric oncology patients, the effects of age and chemotherapy on, 754
Glipizide, pharmacokinetics and pharmaco-dynamics of after once-daily and divided doses, 465
Gram-negative sepsis, sepsis syndrome and associated sequelae in patients at high risk for, 66

- H -

Hemodiafiltration, continuous arteriovenous, variable disposition of ciprofloxacin in critically ill patients undergoing, 236
Hemodialysis, acetazolamide toxicity and pharmacokinetics in patients receiving, 522
Hemodynamic effects of oral cimetidine, ranitidine, and famotidine, comparative evaluation of as determined by echocardiography, 158
Heparin monitoring in acute thrombosis associated with antiphospholipid antibody syndrome, 517
Hepatic function, comparison of quantitative methods to assess: Pugh's classification, indocyanine green, antipyrine, and dextromethorphan, 693
Hepatic metabolic activity, assessment of the time course of drugs with inhibitory effects on, using successive salivary caffeine tests, 781
Herpesvirus infections in the healthy host, management of, 43S
High-performance capillary electrophoresis in the pharmaceutical sciences, 1
Hypercholesterolemia, use of community pharmacy data bases to identify patients at high risk for, 292
Hyperkalemia associated with high-dose trimethoprim-sulfamethoxazole in a patient with the acquired immunodeficiency syndrome, 793

- I -

Immunoglobulin, acute renal failure after administration of intravenous: review of the literature and case report, 765
Indocyanine green, comparison of quantitative methods to assess hepatic function, Pugh's classification, antipyrine, and dextromethorphan, 693
International normalized ratio and prothrombin time over 24 hours in warfarin-treated patients, variations in, 709
International pharmacy, 586
Interstitial nephritis, nabumetone-associated, 669
Intraabdominal infection, mixed infections, considerations for therapy of, 15S
Intraabdominal infections, piperacillin-tazobactam pharmacokinetics in patients with, 472
Intranasal L-threo-3,4,-dihydroxyphenylserine in treating diarrhea associated with familial amyloidotic polyneuropathy, 345
Iron dextran injection, falsely decreased total serum calcium concentration associated with, 789
Isoflurane versus balanced anesthesia, effect on rocuronium's pharmacokinetics and infusion requirement, 36

- L -

Lamotrigine, comprehensive evaluation of, 129
Leukemia or other hematologic disease, pharmacokinetics of fluconazole, in immune-compromised children with, 52
Leukemia, renal function and methotrexate clearance in children with newly diagnosed, 144
Lipoprotein(a) levels in patients with premature coronary heart disease, the effect of high-dose ascorbate supplementation on, 458
Lovastatin-treated hypercholesterolemic patients, the effect of supplemental dietary fat on plasma cholesterol levels in, 565

- M -

Managed care, use of cost-consequence models in, 59S
Mesalazine- and sulfasalazine-associated blood disorders, the risk of, 176
Methotrexate clearance and renal function, in children with newly diagnosed leukemia, 144
Metoprolol kinetics, β_2-receptor activity (lymphocyte), and response to metoprolol in hypertensive black men, 150
Metronidazole plus cefotaxime vs cefoxitin and ampicillin plus sulbactam, comparison of the pharmacodynamic activity of, 479
Midazolam and fentanyl infusion, severe withdrawal syndrome possibly associated with cessation of, 665
Mixed infections, considerations for therapy of, focus on intraabdominal infection, 15S
Mixed infections, rationale and experience in treating suspected hospital-based, 22S
Morphine in trauma patients, current patterns of prescribing and administering, 210

- N -

Nabumetone-associated interstitial nephritis, 669
Narrow therapeutic index drugs, bioequivalence and, 433
Neuromuscular blockade, prolonged, in two critically ill patients treated with atracurium, 254

Nifedipine, the effect of prophylactic on renal function in patients administered contrast media, 59
Nitroprusside use and assessment of the potential risk of cyanide poisoning, a retrospective study of, 773
Nutrition support pharmacy specialists, analysis of the practice of, 806

- O -

Obese patients with stable renal function in the intensive care unit, accuracy of estimated creatinine clearance in, 747
Octreotide- or trimethoprim-induced hyperkalemia? (commentary), 814
Organic base transporter in a cultured renal epithelium, interaction of 3′-azido-3′-deoxythymidine with the, 338
Outcome analysis of a pharmacist-managed anticoagulation service, 732

- P -

Pain management in critically ill patients, analysis of, 592
Paroxetine, adverse events after the abrupt discontinuation of, 778
Peptic acid diseases in a VA ambulatory care clinic, the development of practice guidelines for treatment of, 608
Pharmacists' clinical interventions, cost savings, and workload activities, a computerized system to improve documentation and reporting of, 220
Phenytoin malabsorption after jejunostomy tube delivery, 801
Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections, 472
Plasmapheresis and the removal of tobramycin, evaluation of, 673
Pneumonia, nosocomial, aminoglycoside therapy in combination with a β-lactam agent in critically ill patients, pharmacist-managed, 216
Pneumonia, nursing home-acquired, outcomes from a clinical process improvement program, 33S
Practice guidelines, the development of for treatment of peptic acid diseases in a VA ambulatory care clinic, 608
Pravastatin, effects of on plasma lipid concentrations in poloxamer 407-induced hyperlipidemic rats, 92
Prescription benefits managers, vertical integration: the drug industry and, 265
Propofol, computer-assisted continuous infusion for the delivery of target-controlled infusions of, during outpatient surgery, 512
Prothrombin time and international normalized ratio over 24 hours in warfarin-treated patients, variations in, 709
Psychotropic drug use in relation to psychiatric symptoms in community-living persons with Alzheimer's disease, 495
Publication rates in U.S. schools and colleges of pharmacy, 1976–1992, 487
Pugh's classification, comparison of quantitative methods to assess hepatic function, indocyanine green, antipyrine, and dextro-methorphan, 693

- Q -

Quality improvement, quantitative methods for, 27S
Quality of life in patients with metastatic colorectal cancer receiving chemotherapy: 5-FU versus 5-FU with leucovorin, 600

- R -

Ranitidine and cimetidine administration, the effect of, with zidovudine, 701
Ranitidine and sucralfate, effects of on aluminum concentrations in elderly volunteers, 742
Ranitidine, cimetidine, and famotidine, compara-tive evaluation of the hemodynamic effects of oral, as determined by echocardiography, 158
Ranitidine, the effect of three different dosage regimens on reducing gastric acidity and volume in ambulatory surgica patients, 170
Refeeding syndrome: an approach to understanding its complications and preventing its occurrence, 713
Renal epithelium, cultured, interaction of 3′-azido-3′-deoxythymidine with the organic base transporter in a, 338
Renal function and methotrexate clearance in children with newly diagnosed leukemia, 144
Rewards and advancements for clinical pharmacy practitioners, 99
Rocuronium's pharmacokinetics and infusion requirement, effect of isoflurane versus balanced anesthesia on, 36

- S -

Sepsis syndrome and associated sequelae in patients at high risk for gram-negative sepsis, 66
Sodium bicarbonate, effect of high-dose on the vasopressor effects of epinephrine during cardio-pulmonary resuscitation, 660
Stereochemical aspects of pharmacotherapy, 551
Sucralfate and ranitidine, effects of on aluminum concentrations in elderly volunteers, 742
Sulfamethoxazole-trimethoprim, trimethoprim, and cephalexin, uncommon serious drug toxicity, a large population-based follow-up study of, 428
Sulfasalazine- and mesalazine-associated blood disorders, the risk of, 176

- T -

Talc, bleomycin, and the tetracyclines in the treatment of malignant pleural effusions, update on, 228
Tetracyclines, talc, and bleomycin, in the treatment of malignant pleural effusions, update on, 228
Theophylline oral dosage forms, revised FDA labeling

guideline for, 409
Theophylline overdose, charcoal hemoperfusion for, a case report and proposal for predicting treatment time, 621
Theophylline treatment of apnea of prematurity, accuracy and reliability of dosing equations to individualize, 246
Theophylline, therapeutic equivalence of a generic slow-release tablet, 26
Therapeutic equivalence of a generic slow-release theophylline tablet, 26
Thrombolytic-associated cholesterol emboli syndrome: case report and literature review, 441
Thrombosis, acute, associated with antiphospholipid antibody syndrome, heparin monitoring in, 517
Tobramycin, evaluation of plasmapheresis for the removal of, 673
Torsades de pointes and QT interval prolongation and due to erythromycin lactobionate, 687
Toxic epidermal necrolysis after initiation of felbamate therapy, 260
Train-of-four monitoring in a critically ill paralyzed patient, inconsistency with, 540
Train-of-four: to use or not to use, 546
Transaminase, drug-associated asymptomatic elevations of in drug safety assessments, 23
Trimethoprim-sulfamethoxazole, hyperkalemia associated with high-dose in a patient with the acquired immunodeficiency syndrome, 793
Trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin, uncommon serious drug toxicity, a large population-based follow-up study of, 428

- V -

Valproate, the emerging role of in bipolar disorder and other psychiatric disorders, 631
Vancomycin prescribing, inappropriate, based on criteria from the Centers for Disease Control and Prevention, 579
Vancomycin serum concentrations, association of with outcomes in patients with gram-positive bacteremia, 85
Vancomycin-resistant enterococci, 682, 684
Varicella-zoster virus infections, cost-consequence models for, 49S
Vertical integration: the drug industry and prescription benefits managers, 265

- Z -

Zidovudine, pharmacokinetics and pharmacodynamics of high-dose, administered as a continuous infusion in patients with cancer, 451
Zidovudine, the effect of cimetidine and ranitidine administration with, 701
Zimbabwe, a community-based clinical pharmacy teaching, research, and service program in, 614